Medtronic, Inc. Announces Start of International Study Comparing Endeavor(R) Resolute Drug-Eluting Stent to Abbott Laboratories’s Xience(R) V

MINNEAPOLIS--(BUSINESS WIRE)--Continuing its commitment to clinical excellence, Medtronic, Inc. (NYSE: MDT), today announced the start of an international study comparing the company’s Endeavor® Resolute Zotarolimus-Eluting Coronary Stent with Abbott Laboratory’s Xience® V Everolimus-Eluting Coronary Stent. The first implants in the study, called the RESOLUTE III All-Comers Trial, took place in Europe during the last two weeks.